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Abstract
Introduction: hPTTG1 (human pituitary tumor-transforming gene 1) is an oncogene overexpressed in breast cancer
and several other types of cancer. Increased hPTTG1 expression has been shown to be associated with poor
patient outcomes in breast cancer. Although hPTTG1 overexpression plays important roles in promoting the
proliferation, invasion, and metastasis of cancer cells, it also has been suggested to induce cellular senescence.
Deciphering the mechanism by which hPTTG1 overexpression induces these contradictory actions in breast cancer
cells is critical to our understanding of the role of hPTTG1 in breast cancer development.
Methods: MCF-10A and MCF-7 cells were used to identify the mechanism of hPTTG1-induced senescence. The
interplay between hPTTG1 overexpression and chemokine C-X-C motif receptor 2 (CXCR2)/p21-dependent
senescence in tumor growth and metastasis of MCF-7 cells was investigated by orthotopic transplantation of
severe combined immunodeficiency (SCID) mice. Additionally, human invasive ductal carcinoma (IDC) tissue arrays
were used to confirm the hPTTG1/CXCR2/p21 axis established in vitro.
Results: In this study, we investigated the mechanism of hPTTG1-induced senescence as well as its role in breast
cancer progression and metastasis. Herein, we showed that hPTTG1 overexpression reinforced senescence through
the CXCR2/p21 signaling. Furthermore, hPTTG1 overexpression activated NF-B signaling to transactivate the
expression of interleukin (IL)-8 and growth-regulated oncogene alpha (GROa) to execute CXCR2 signaling in MCF-7
cells. When CXCR2 expression was knocked down in hPTTG1-overexpressing MCF-7 cells, hPTTG1-induced
senescence was abrogated by alleviating CXCR2-induced p21 expression. In a mouse model, CXCR2-mediated
senescence limited hPTTG1-induced tumor growth and metastasis. Moreover, CXCR2 knockdown in hPTTG1-
overexpressing MCF-7 tumors dramatically accelerated tumor growth and metastasis. Our in vitro and in vivo results
demonstrated that hPTTG1 overexpression reinforces senescence through CXCR2 signaling, and the evasion of
CXCR2/p21-dependent senescence was critical to hPTTG1 exerting its oncogenic potential. Interestingly, although
CXCR2-dependent senescence restrained hPTTG1-induced tumor progression, when MCF-7 cells and hPTTG1-
overexpressing MCF-7 cells were co-transplanted into the mammary fat pads of SCID mice, hPTTG1-overexpressing
senescent cells created a metastasis-promoting microenvironment that promoted lung metastasis of the MCF-7
cells. Immunohistochemical analysis of human breast tumor samples also confirmed the importance of the
hPTTG1/CXCR2 axis in promoting breast cancer metastasis.
Conclusions: Our findings provide novel molecular insights into hPTTG1-induced senescence and identify a novel
mechanism by which hPTTG1 promotes metastasis by regulating the senescence-associated microenvironment.
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Introduction
PTTG1 is an oncogene first isolated from rat pituitary
tumor cells [1]. In mouse 3T3 fibroblasts, PTTG1 over-
expression limits cell proliferation but promotes cell
transformation [1]. In human cells, hPTTG1 has been
characterized as a cell-cycle regulator that regulates the
separation of sister chromatids [2] and plays important
roles in cancer cell transformation and tumorigenesis
[3]. Increased expression of hPTTG1 has been observed
to be associated with poor prognosis in several types of
human cancers [4-8]. In breast cancer, hPTTG1 overex-
pression is a proliferation marker [9] and can be consid-
ered a prognostic marker or a molecular signature of
metastasis and recurrence [10,11].
When hPTTG1 is overexpressed, it exerts an oncogenic
potential to enhance the proliferation, invasion, and
metastasis of cancer cells [12-15]. In our previous study,
we demonstrated that hPTTG1 can regulate the actin
cytoskeletal dynamics of breast cancer cells by activating
GEF-H1/RhoA signaling to promote breast cancer metas-
tasis [13]. In contrast to its oncogenic properties, hPTTG1
also is suggested to be involved in the regulation of senes-
cence. In pituitary tumor cells, either the depletion or
overexpression of hPTTG1 induces chromosomal instabil-
ity and executes p21-dependent senescence [16-18]. In
human fibroblasts and colorectal cancer cells, hPTTG1
overexpression induces the DNA-damage response (DDR)
to trigger p53-dependent senescence [19]. Deciphering the
mechanism by which hPTTG1 overexpression regulates
these contradictory actions is critical to our understanding
of the role of hPTTG1 in cancer development.
Oncogene-induced senescence (OIS) is a barrier to
oncogene-induced tumor growth and malignant progres-
sion that works by placing cancer cells into an irreversible
state of cell-cycle arrest [20,21]. Although senescence has
dramatic tumor-suppression effects via the inhibition of
tumor growth, accumulating evidence suggests that senes-
cence may be both beneficial and detrimental for patient
outcomes [20,22,23]. To reinforce OIS, cells secrete a
number of cytokines and chemokines to construct a senes-
cence-promoting microenvironment [24,25]; this secretory
behavior is known as the senescence-associated secretory
phenotype (SASP). For example, senescent human fibro-
blasts increase their expression of IL-8 and GROa to acti-
vate CXCR2 signaling, which reinforces senescence [25].
However, the misuse of SASP factors by cancer cells may
support their proliferation and induce a chronic inflamma-
tory response [26].
CXCR2 is a G protein-coupled receptor that is acti-
vated by CXC chemokines including IL-8, GROa, GROb,
and GROg. The increased expression of CXCR2 has been
suggested to promote tumor growth, angiogenesis, and
metastasis in head and neck cancer, non-small-cell lung
cancer, ovarian cancer, and melanoma [27]. IL-8/CXCR2
signaling exerts its oncogenic potential by activating the
Akt/mTOR, MAPK, and androgen-receptor pathways
[28]. Similar to hPTTG1, CXCR2 promotes malignant
progression in certain types of cancer and triggers senes-
cence in human normal fibroblasts [25]. These findings
suggest that CXCR2 plays important roles in both tumor
suppression and promotion. In breast cancer, the role of
CXCR2 in cancer development and metastasis remains
unclear [29].
In this study, we aimed to elucidate the mechanism of
hPTTG1-induced senescence and to understand its
role in breast cancer progression. Herein, we provided
a novel link between hPTTG1 overexpression and
CXCR2-dependent senescence. In breast cancer cells,
hPTTG1 overexpression reinforces OIS through a
CXCR2/p21 signaling. Although CXCR2-dependent
senescence dramatically inhibits the tumor growth of
hPTTG1-overexpressing MCF-7 cells, hPTTG1-induced
SASP remodels the tumor microenvironment to pro-
mote the metastasis of neighboring nonsenescent cancer
cells. In summary, we provide novel insights into how
hPTTG1-induced senescence contributes to breast
cancer metastasis.
Materials and methods
Cell culture and reagents
The following cell lines were used in this study: breast
cancer cell lines MDA-MB-231, MCF-7, T-47D, and AU
565; human normal mammary epithelial cell line MCF-
10A; and colorectal cancer cell lines HCT116 and p53-null
HCT116. MDA-MB-231, MCF-7, T-47D, and AU 565
cells were grown in Dulbecco modified Eagle medium
(DMEM) (Sigma-Aldrich, St. Louis, MO, USA) containing
10% fetal bovine serum. MCF-10A cells were grown in
DMEM/F12 medium (GIBCO BRL, Eggenstein, Germany)
containing 5% horse serum, 10 μg/ml insulin, 20 ng/ml
EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone,
and 100 units/ml penicillin/streptomycin. HCT116 and
p53-null HCT116 colorectal tumour cells (from Dr. Bert
Vogelstein of the Johns Hopkins School of Medicine) were
maintained in McCoy 5A medium containing 10% fetal
bovine serum. Cells were grown at 37°C in a 5% CO2
atmosphere. The hPTTG1 expression plasmid was
obtained from our laboratory [13]. The CXCR2 expression
plasmid was purchased from ORIGENE Inc. (SC323957;
Rockville, MD, USA) and subcloned into the pcDNA3.1
vector (Invitrogen, Carlsbad, CA, USA).
SB225002 (an antagonist of CXCR2, 10 μM; Calbio-
chem, San Diego, CA, USA) or JSH-23 (an inhibitor of the
NF-B transcription factor, 10 μM; Calbiochem) was
added to the cells, and 0.001% DMSO (vehicle) was added
as a control. For neutralization of CXCR2 and IL-8, anti-
CXCR2 antibody (5 μg/ml, MAB331; R&D Systems Inc.,
Minneapolis, MN, USA) or anti-IL-8 antibody (1 μg/ml,
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AF-208-NA; R&D Systems) was added to the cells, and
isotype anti-IgG antibody (5 μg/ml, MAB003; R&D Sys-
tems) was added as a control (Control IgG).
Generation of stable selected cells
To generate the stable selected pools, MCF-7 and MCF-
10A cells were stably transfected with 4 μg of the
pcDNA3.1 empty vector (stable mock-transfected MCF-
7/MCF-10A cells) or the pcDNA3.1-hPTTG1 expression
plasmid (stable hPTTG1-overexpressing MCF-7/MCF-
10A cells) by using Lipofectamine 2000 (Invitrogen) and
were then selected with hygromycin (100 μg/ml).
For the puromycin selection of stable knockdown cells,
lentiviruses encoding specific shRNAs were produced by
following the established protocol provided by the National
RNAi Core Facility, Academia Sinica (Taipei, Taiwan) [30].
The specific shRNA reagents targeting p53 and p21
(shp53-1:TI379448, shp53-2:TI379451, shp21-1:TI321870,
and shp21-2:TI321871) were purchased from Origene Inc.
(Rockville, MD, USA). The specific shRNA reagents target-
ing CXCR2 (shCXCR2-1:TRCN0000009138, shCXCR2-2:
TRCN0000009136) and GFP (shGFP: TRCN0000072178)
were obtained from the National RNAi Core Facility,
Academia Sinica (Taipei, Taiwan).
Immunoblot analysis
The immunoblot analysis was performed as previously
described [13] with antibodies against Rb (no. 9309), p-Rb
(9307), p21 (2947), IKKa (2682), IKKb (2370), p-p65
(3033), p65 (8242), p-Erk1/2 (4370), p-p53ser15 (9286), g-
H2AX (9718) (Cell Signaling Technology, Beverly, MA,
USA), p53 (SC-126), p16INK4A (SC-1661), Erk1/2 (SC-94),
b-actin (SC-1616) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), or hPTTG1 (34-1500, Invitrogen).
Cytokine array
Cytokine arrays were used to determine the relative levels
of 36 different cytokines and chemokines. The array was
performed by using the protocol provided by the manufac-
turer (Ary005; R&D Systems). After development, the
films were scanned, and the images were quantified by
using Image J (National Institutes of Health, USA).
Senescence-associated b-galactosidase (SA-b-Gal) assay
SA-b-Gal assays were performed according to the manu-
facturer’s instructions (Millipore, Billerica, MA, USA). In
brief, the cells were fixed and incubated at 37°C in a solu-
tion containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-
galactoside (X-gal) for 12 hours. After staining, 250 cells
were counted for each sample.
Luciferase reporter assays
The 5’ regulatory sequences of CXCR2 (nucleotides
-1,469 to +40, which spans 1,469 bp upstream to 40 bp
downstream of the transcription start site), IL-8 (nucleo-
tides -875 to +1, which spans 875 bp upstream to 1 bp
downstream of the transcription start site), and GROa
(nucleotides -1,442 to +52, which spans 1,442 bp
upstream to 52 bp downstream of the transcription start
site) were polymerase chain reaction (PCR) amplified
from human genomic DNA and inserted into the pGL4
luciferase vector (Promega, Madison, WI, USA). The IL-
8 regulatory sequence (pGL4-IL8) contains one NF-B
binding site (-82/-72). In the mutated IL-8 promoter
(pGL4-IL8M), the NF-B binding sequence was replaced
with the Bgl II sequence (AGATCT) with a standard
cloning procedure. The GROa regulatory sequence
(pGL4-GROa) contains one NF-B binding site (-77/-
67). The NF-B binding site deleted mutant (pGL4-
GROaM) spans 1,442 bp upstream to 80 bp upstream of
the transcription start site of the GROa regulatory
sequence (-1,442/-80). MCF-7 cells were transfected by
using Lipofectamine 2000 (Invitrogen), and the luciferase
activities were measured 48 hours after transfection by
using the Dual-Luciferase Reporter System (Promega).
RNA isolation and quantitative RT-PCR (qRT-PCR)
Cytosolic RNA was isolated from confluent cultures in
10-cm cell cultures with a Trizol reagent kit (Invitrogen)
according to the manufacturer’s instructions. RNA was
converted to cDNA with the SuperScript III First-Strand
Synthesis System (Invitrogen). qRT-PCR was performed
according to the manufacturer’s instructions by using
ABI 7300 (Applied Biosystems).
FACS (fluorescence-activated cell sorting) analysis
The expression of CXCR2 was evaluated in cells obtained
from cell culture with a FACScan (Becton Dickinson, San
Jose, CA, USA). A fluorescein isothiocyanate (FITC)-con-
jugated anti-CXCR2 antibody (no. 551126) or FITC-conju-
gated isotype anti-IgG antibody (no. 555748) (Becton
Dickinson) was used in the staining procedure according
to the instructions of the manufacturer.
ELISA (enzyme-linked immunosorbent assay)
Conditioned media were collected from 5 × 105 cells after
a 48-hour incubation. The concentrations of IL-8 and
GROa in the supernatant were measured with specific
ELISA kits (PEPROTECH, Rocky Hill, NJ, USA)
BrdU and cell-growth assays
BrdU colorimetric assays were performed by following
the manufacturer’s instructions (Roche, Mannheim,
Germany). In brief, cells were labeled with BrdU for
8 hours. After labeling, the cells were fixed and the DNA
denatured. A monoclonal anti-BrdU antibody was used to
bind the incorporated BrdU. After washing, TMB sub-
strates were added, and the absorbance measured in an
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ELISA reader at 370 nm. For the cell-growth assay, 5 × 104
cells were seeded in six-well plates, and growth curves
were obtained by daily cell counts.
ChIP assay
The ChIP assay was performed according to the protocol
of ChIP assay kit (Millipore). The chromatin preparation
and ChIP reactions were performed as previously
described [13]. qRT-PCR was used to enrich promoter
binding levels, and those data are expressed as fold enrich-
ment (fold increase over the control IgG). qRT-PCR was
carried out with the following primers: IL-8 p65 binding
site forward, 5’-GGTTTGCCCTGAGGGGATG-3’ and
reverse, 5’-CCTACTAGAGAACTTATGCACCCTCATC-
3’; GROa p65 binding site forward, 5’- GGACTCGGG
ATCGATCTGG-3’ and reverse, 5’-GTGGCTCTCCGA-
GATCCGC-3’.
Animal studies
All experiments involving mice were performed with
approval of the Laboratory Animal Center at Tzu-Chi
University. For the spontaneous metastasis assay, 5 × 105
cells were injected into the fourth mammary fat pad of 5-
to 8-week-old SCID mice in 1:1 Matrigel (Becton Dickin-
son) plus PBS. Tumor growth on orthotopic implantation
was measured weekly. Lungs from mice bearing the indi-
cated tumors were isolated after 12 and 14 weeks. All dis-
sected lungs were paraffin-embedded, sectioned, and
stained with H&E, and the metastatic nodules were
counted as previously described [13].
Immunohistochemistry
Tissue samples from patients with breast cancer (100
patients, Biomax, BC081120) and those with breast cancer
with matched metastatic carcinoma of the lymph node
(50 patients, Biomax, BR1005) were purchased from US
Biomax, Inc. (Rockwell, MD, USA). All tissues were col-
lected by Biomax according to the HIPAA-approved pro-
tocol for ethical standards after receiving patient consent.
IHC was performed as previously described [13]. The
appropriate volume of diluted primary anti-hPTTG1
(1:100, 34-1500, Invitrogen), anti-CXCR2 (1:80, ab14935,
Abcam) or anti-p21 (1:50, 2947, Cell Signaling) antibody
was added to cover the specimen, and the samples were
incubated at 4°C overnight. Nuclei were then counter-
stained with hematoxylin.
To evaluate the expression levels of hPTTG1, CXCR2,
and p21, immunostained human breast tissues or meta-
static carcinomas were judged by two pathologists by
using the following criteria. The criteria for hPTTG1 eva-
luation were described in our previous study [13]. For p21,
the classifications included 3+ (strong p21 nuclear staining
in > 10% tumor cells), 2+ (positive p21 nuclear staining in
> 5% tumor cells), and 0/1+ (no or positive p21 nuclear
staining in < 5% tumor cells). CXCR2 was classified as
strong (3+), moderate (2+), or weak (0/1+) based on the
intensity of both membrane and cytoplasmic immunoreac-
tivity. The association of the expression of hPTTG1 with
CXCR2 expression in invasive breast carcinoma was ana-
lyzed by using the Pearson c2 correlation test.
Migration and invasion assays
For the migration assays, stable ZsGreen-labeled MCF-7
cells (0.5 × 105) and stable mock-transfected MCF-7 (0.5 ×
105) or stable hPTTG1-overexpressing MCF-7 (0.5 × 105)
cells were mixed and seeded in a uncoated membranes
with 8.0-μm pores (Corning, Santa Clara, CA, USA). For
the invasion assays, stable ZsGreen-labeled MCF-7 cells
(0.5 × 105) and stable mock-transfected MCF-7 (0.5 × 105)
or stable hPTTG1-overexpressing MCF-7 (0.5 × 105) cells
were mixed and seeded in a Matrigel-coated chamber with
8.0-μm pores (Becton Dickinson). Cells were seeded in
serum-free medium and migrated toward the growth
media containing 1% fetal bovine serum for 48 hours. The
fluorescent migrating or invading cells in polycarbonate
membranes were counted, as previous reported [31].
Statistical analysis
Data are presented as the mean ± SEM unless otherwise
noted. The Student t test was used for comparisons.
A level of P < 0.05 was considered significant.
Results
hPTTG1 overexpression reinforces senescence in breast
cancer and normal breast epithelial cells
In our previous study, we found hPTTG1 to be endogen-
ously overexpressed in the metastatic MDA-MB-231
breast cancer cell line and expressed at very low levels in
the nonmetastatic MCF-7 breast cancer cell line and nor-
mal mammary epithelial cells [13] (Figure 1A). In addition,
hPTTG1 overexpression enhanced the motility and inva-
siveness of both MDA-MB-231 and MCF-7 cells by acti-
vating GEF-H1/RhoA signaling [13]. Interestingly,
although knockdown of hPTTG1 expression in MDA-
MB-231 cells attenuated the tumor growth of these cells
in an orthotopic mouse model [13], ectopic overexpression
of hPTTG1 in MCF-7 cells also significantly reduced the
tumor size and growth rate of MCF-7 cells (Figure 1B, C).
Because hPTTG1 overexpression has been demon-
strated either to inhibit cell proliferation [1,32] or to
induce senescence [17,19], we therefore asked whether
hPTTG1 overexpression induces senescence in breast
cancer cells. To assess the effect of hPTTG1 overexpres-
sion on senescence in breast cancer, we used MCF-10A
normal breast epithelial cells and MCF-7 breast cancer
cells, both of which endogenously express very low levels
of hPTTG1 (Figure 1A). By measuring the activity of
senescence-associated b-galactosidase (SA-b-Gal), we
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Figure 1 hPTTG1 overexpression reinforces senescence and senescence-associated secretory phenotype (SASP). (A) Cell lysates of MDA-
MB-231, MCF-7, and MCF-10A cells were collected for immunoblot analysis. (B) MCF-7 cells stably transfected with pcDNA3.1 (Mock; MCF-7Mock)
or pcDNA3.1-hPTTG1 (hPTTG1; MCF-7hPTTG1) were orthotopically injected into fourth mammary fat pads of SCID mice. The primary tumor weights
were measured 18 weeks after implantations. Representative tumors are shown in the upper panel. Quantitative results are shown in the lower
panel (n = 6 per group). The results are presented as the mean ± SEM. *P < 0.05. (C) Tumor growth was measured weekly after orthotopic
implantations of MCF-7 cells stably transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1). The experiments were terminated 18 weeks
after implantation. Representative tumors are shown in (B). n = 6 per group per time point. Each time point shows the mean ± SEM. *P < 0.05.
(D) MCF-7 and MCF-10A cells stably transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1) were plated for the senescence assay. The
percentage of positively stained cells is indicated to the right of the respective images. Data represent mean ± SEM (n = 3). ***P < 0.0001.
(E) Cell lysates were collected from MCF-7 and MCF-10A cells stably transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1) for
immunoblot analysis. WT, untransfected cells. (F) Conditioned media were collected from MCF-7 cells stably transfected with pcDNA3.1 vector
(Mock) or pcDNA3.1-hPTTG1 (hPTTG1) for cytokine array analysis. The differences are indicated with boxes. (G) The pixel intensity of (F) was
analyzed by using Image J software.
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found that hPTTG1 overexpression significantly rein-
forced senescence in both cell lines (Figure 1D). hPTTG1
overexpression has been shown to induce senescence
through p53- or p21-dependent pathways [17,19].
Indeed, in both cells, hPTTG1 overexpression increased
the expression of the p53 and p21 (Figure 1E). In addi-
tion, hPTTG1 overexpression increased the expression of
the p16INK4A in MCF-7 cells but not in MCF-10A cells,
and the expression and phosphorylation of Rb was not
significantly altered by hPTTG1 overexpression in both
cell lines (Figure 1E). p53/p21 and p16/pRb are two
major pathways involved in OIS regulation [21]. These
results suggest that hPTTG1 overexpression may rein-
force senescence through p53/p21 but not p16/pRb sig-
naling in breast cancer and normal breast epithelial cells.
SASP is a specific characteristic of senescent cells
responsible for generating the senescence-promoting
microenvironment [26]. To confirm further whether
hPTTG1 overexpression can induce SASP in breast cancer
cells, we used antibody arrays to monitor the expression
profile of secreted cytokines in the conditioned media
from stable mock-transfected (MCF-7Mock) and stable
hPTTG1-overexpressing MCF-7 cells (MCF-7hPTTG1,
MCF-7 cells stably transfected with pcDNA3.1-hPTTG1
expression plasmid). As expected, hPTTG1 overexpression
specifically induced the expression of certain inflammatory
cytokines and chemokines, including IL-8, GROa, TNF-a,
and Serpin E1 (Figure 1F, G). These results indicate that
hPTTG1 overexpression induces senescence and SASP in
breast cancer cells.
hPTTG1 overexpression co-upregulates the CXCR2
receptor and its ligands
With antibody arrays, we determined that hPTTG1 over-
expression led to a considerable induction in IL-8 and
GROa. Because the antibody arrays were semiquantita-
tive, we performed ELISA (enzyme-linked immunosor-
bent assay) analyses to confirm this result (Figure 2A).
Both IL-8 and GROa are ligands of CXCR1/2 receptors,
and the IL-8/CXCR2 axis has been reported to reinforce
OIS [25]. Thus, we next investigated whether hPTTG1
could upregulate the expression of CXCR2 during
hPTTG1-induced senescence. By using quantitative RT-
PCR (qRT-PCR), we found that hPTTG1 overexpression
significantly induced the mRNA expression of CXCR2
but not CXCR1 in MCF-7 cells (Figure 2B). By using
qRT-PCR and fluorescence-activated cell sorting (FACS)
analysis, we confirmed that the expression level of
CXCR2 was significantly induced by hPTTG1 overex-
pression in both MCF-10A and MCF-7 cells that endo-
genously express both hPTTG1 and CXCR2 at very low
levels (Figure 2C, D).
To investigate further the mechanism by which hPTTG1
upregulates the expression of CXCR2 and its ligands, we
performed luciferase reporter analysis on 5’ upstream reg-
ulatory sequences of CXCR2, IL-8, and GROa. The results
demonstrated that hPTTG1 overexpression enhances
the transcriptional activities of the CXCR2, IL-8, and
GROa promoters (Figure 2E), suggesting that hPTTG1
co-upregulates the expression of CXCR2 and its ligands
through transcriptional regulation.
NF-B is a core transcription-factor complex involved
in the inflammatory response and cancer development
[33]. The activation of NF-B signaling plays important
roles in enhancing SASP when senescence is induced
[23,34]. To elucidate further how hPTTG1 regulates the
expression of CXCR2 ligands, we screened the expression
and phosphorylation status of proteins associated with
the NF-B pathway. The results demonstrated that
hPTTG1 overexpression increased the expression of
IKKb but not IKKa (Figure 2F). Moreover, hPTTG1
overexpression enhanced the phosphorylation of p65,
which is the major component of the NF-B complex
(Figure 2F). This result supports the previous finding that
IKKb and p65 play roles in the regulation of CXCR2
ligands [25]. Furthermore, in hPTTG1-overexpressing
MCF-7 cells, deletions of the NF-B binding site [35,36]
eliminated the luciferase activity of the IL-8 and GROa
promoters (Figure 2G, H). These results were further
confirmed by ChIP (chromatin immunoprecipitation)
assay, which revealed that the binding capacities of p65
were enhanced by hPTTG1 overexpression (Figure 2I). In
addition, when MCF-7hPTTG1 cells were treated with a
p65-specific inhibitor (JSH-23), the secretion of IL-8 and
GROa was also alleviated (Figure 2A). These results indi-
cate that hPTTG1 overexpression activates NF-B signal-
ing to enhance the expression of IL-8 and GROa.
hPTTG1-induced senescence is CXCR2/p21 dependent
Because hPTTG1 overexpression co-upregulates the
expression of CXCR2 and its ligands, we next asked
whether hPTTG1 reinforces OIS through CXCR2 signal-
ing. To this end, we knocked down the expression of
CXCR2 in MCF-7hPTTG1 cells by using CXCR2-specific
shRNA; the level of CXCR2 knockdown was confirmed
by qRT-PCR (Figure 3A). Indeed, CXCR2 knockdown
dramatically limited the hPTTG1-induced senescence
(Figure 3B). CXCR2 reinforces OIS through a p53/p21-
dependent pathway [25], and p21 has been indicated to
inhibit cell proliferation when hPTTG1 is overexpressed
[17,32]. As expected, the depletion of CXCR2 reduced
the expression of the p21 protein induced by hPTTG1
overexpression (Figure 3C). Moreover, the depletion of
p21 actually abrogated the hPTTG1-induced senescence
in MCF-7 cells (Figure 3D, E). When MCF-7hPTTG1 cells
were treated with a CXCR2 antagonist (SB225002),
or when CXCR2 and IL-8 were neutralized by specific
antibodies, the inhibition of IL-8/CXCR2 signaling
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Figure 2 hPTTG1 overexpression upregulates the expression of CXCR2, IL-8, and GROa. (A) Conditioned media were collected from MCF-
7Mock or MCF-7hPTTG1 cells treated with vehicle control (DMSO) or an NF-B inhibitor (JSH-23) for ELISA analysis of IL-8 (upper panel) and GROa
(lower panel). Unconditioned DMEM media acted as negative control. (B) CXCR1 (upper panel) and CXCR2 (lower panel) mRNA expression was
analyzed with qRT-PCR in MCF-7Mock and MCF-7hPTTG1 cells. (C) hPTTG1 and CXCR2 mRNA expression was analyzed with qRT-PCR in MCF-7Mock,
MCF-7hPTTG1, MCF-10AMock, MCF-10AhPTTG1, and MDA-MB-231 cells. (D) MCF-10AMock, MCF-10AhPTTG1, MCF-7Mock, and MCF-7hPTTG1 cells were
stained with a FITC-conjugated anti-CXCR2 antibody for FACS analysis. (E) The regulatory sequences of IL-8, GROa, and CXCR2 were co-
transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1) into MCF-7 cells for luciferase reporter assays. (F) Cell lysates were collected
from untransfected MCF-7 (WT), MCF-7Mock, and MCF-7hPTTG1cells for immunoblot analysis. (G) The pGL4 vector (Mock), IL-8 promoter, or the
mutated IL-8 promoter was transiently cotransfected with pcDNA3.1-hPTTG1 expression plasmid into MCF-7 cells for luciferase reporter assays.
(H) The pGL4 vector (Mock), GROa promoter, or the NF-B binding site deleted mutant was transiently cotransfected with the pcDNA3.1-hPTTG1
expression plasmid into MCF-7 cells for luciferase reporter assays. (I) ChIP assays were performed on MCF-7Mock or MCF-7hPTTG1 cells. The ChIP-
qPCR data are expressed as the fold increase over the control (IgG) for the promoter region containing p65-binding elements. The results in A
to C, E, and G to I are presented as the mean ± SEM (n = 3). *P < 0.05; **P < 0.01; NS, not significant.
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significantly reduced the hPTTG1-induced p21 expres-
sion (Figure 3F). These results demonstrate that hPTTG1
overexpression reinforces senescence through a CXCR2/
p21-dependent mechanism.
The hPTTG1/CXCR2 axis induces p21 expression through
a p53-independent mechanism
Surprisingly, although p21 is a well-known p53-activated
gene, CXCR2 depletion reduced the expression of p21 in
MCF-7hPTTG1 cells, but p53 expression was not dimin-
ished (Figure 3C). To address this issue, we knocked down
the expression of p53 in MCF-7hPTTG1 cells. In contrast to
CXCR2 depletion, p53 depletion only slightly alleviated
hPTTG1-induced senescence (Figure 4A) and hPTTG1-
induced p21 expression (Figure 4B). This result suggests
that p53 plays only a partial role in hPTTG1/CXCR2-
induced senescence and that the hPTTG1/CXCR2 axis
may induce p21 expression through a p53-independent
mechanism.
hPTTG1 overexpression has been shown to induce p21
expression through a p53-independent mechanism [32].
Therefore, we overexpressed hPTTG1 in T-47D and AU
565 breast cancer cell lines, which carry mutated p53
genes [37]. In both T-47D and AU 565 cells, hPTTG1
overexpression induced the expression of CXCR2 and p21
(Figure 4C, D) and significantly reinforced senescence
Figure 3 hPTTG1 overexpression activates CXCR2/p21 signaling to induce senescence. (A) The level of CXCR2 knockdown was confirmed
with qRT-PCR. The results are presented as the mean ± SEM (n = 3). *P < 0.05. (B) MCF-7hPTTG1 cells stably infected with shGFP, shCXCR2-1, or
shCXCR2-2 were plated for senescence assays. The percentage of positively stained cells is indicated to the right of the respective images. The
results are presented as the mean ± SEM (n = 3). ***P < 0.0001. (C) Cell lysates were collected from MCF-7hPTTG1 cells and MCF-7hPTTG1 cells
stably infected with shGFP, shCXCR2-1, or shCXCR2-2 for immunoblot analysis. (D) MCF-7hPTTG1 cells stably infected with shGFP, shp21-1, or
shp21-2 were plated for the senescence assay. The percentage of positively stained cells is indicated to the right of the respective images. The
results are presented as the mean ± SEM (n = 3). ***P < 0.0001. (E) Cell lysates were collected from MCF-7hPTTG1 cells stably infected with shGFP,
shp21-1, or shp21-2 for immunoblot analysis. (F) Cell lysates were collected from MCF-7hPTTG1 cells treated with DMSO (vehicle), IgG control,
CXCR2 inhibitor (SB225002), anti-CXCR2 antibody, or anti-IL-8 antibody for immunoblot analysis.
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Figure 4 hPTTG1 overexpression activates CXCR2/p21 signaling through a p53-independent mechanism. (A) MCF-7hPTTG1 cells stably
infected with shGFP, shp53-1, or shp53-2 were plated for senescence assays. The percentage of positively stained cells is indicated to the right
of the respective images. The results are presented as the mean ± SEM (n = 3). *P < 0.05. (B) Cell lysates were collected from MCF-7hPTTG1 cells
and MCF-7hPTTG1 cells stably infected with shGFP, shp53-1, or shp53-2 for immunoblot analysis. (C, G) T47-D, AU 565, HCT116, and p53-null
HCT116 cells were transiently transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1), and then these cells were stained with FITC-
conjugated anti-CXCR2 antibody for FACS analysis. (D, H) The cell lysates were collected from T47-D, AU 565, HCT116, and p53-null HCT116 cells
transiently transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1) for immunoblot assays. (E, F) T47-D and AU 565 cells were
transiently transfected with pcDNA3.1 (Mock) or pcDNA3.1-hPTTG1 (hPTTG1), and then these cells were plated for senescence assays. The
percentage of positively stained cells is indicated to the right of the respective images. The results are presented as the mean ± SEM (n = 3). *P
< 0.05; ***P < 0.0001. (I) Schematic representation of the role of p53 in hPTTG1/CXCR2-mediated senescence. (J) Cell lysates were collected from
MCF-7hPTTG1 cells and MCF-7hPTTG1 cells stably infected with shGFP, shCXCR2-1, or shCXCR2-2 for immunoblot analysis. (K) Cell lysates were
collected from MCF-7hPTTG1 cells treated with DMSO (vehicle), IgG control, CXCR2 inhibitor (SB225002), anti-CXCR2 antibody, or anti-IL-8 antibody
for immunoblot analysis.
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(Figure 4E, F). Furthermore, we also overexpressed
hPTTG1 in HCT116 and p53-null HCT116 colorectal
cancer cell lines. The results demonstrated that hPTTG1
overexpression could induce the expression of CXCR2
and p21 in p53-null HCT116 cells (Figure 4G, H). Taken
together, these results suggest that hPTTG1 overexpres-
sion reinforces CXCR2/21-dependent senescence mainly
through a p53-independent mechanism and that the p53-
dependent mechanism only minimally affects hPTTG1-
induced senescence (Figure 4I).
The results described demonstrated that hPTTG1 over-
expression reinforces CXCR2/p21-dependent senescence,
but it remains unclear why CXCR2 depletion increases
p53 expression in MCF-7hPTTG1 cells. OIS has been recog-
nized as a DDR induced by DNA replication stress [38,39],
and both hPTTG1 and CXCR2 are involved in DDRs
[19,25]. Therefore, we hypothesized that hPTTG1 overex-
pression may provoke DDRs to execute senescence. When
the CXCR2-dependent senescence pathway is interrupted
and fails to arrest the cell cycle, hPTTG1 overexpression
may induce higher DNA-replication stress and provoke a
greater p53-dependent DDR. We confirmed this hypoth-
esis by monitoring the phosphorylation of H2AXser139
(gH2AX) and p53ser15, which are important phosphoryla-
tion signals in DDR. Indeed, hPTTG1 overexpression
induced the phosphorylation of gH2AX and p53ser15 in
MCF-7 cells (Figure 4J, lane 2). When CXCR2 was
depleted, hPTTG1 overexpression dramatically induced
stronger phosphorylation of gH2AX and p53ser15 in
CXCR2-depleted MCF-7hPTTG1 cells than in MCF-
7hPTTG1 cells (Figure 4J, lanes 4 and 5). Notably, depleting
CXCR2 in MCF-7hPTTG1 cells also strongly activated the
phosphorylation of Erk1/2, a signaling protein closely
linked to the proliferation status of cancer cells (Figure 4J).
These data indicate that hPTTG1 overexpression induces
higher replication stress and provokes a stronger DDR
when CXCR2 is depleted. Additionally, the phenomenon
that CXCR2 depletion increases p53 expression and allevi-
ates p21 expression in MCF-7hPTTG1 cells provides a pos-
sible explanation for why breast cancers with poor
prognosis demonstrate increased p53 expression but a loss
of p21 expression [40].
Interestingly, unlike the results of CXCR2-depleted MCF-
7hPTTG1 cells (Figure 4J), when MCF-7hPTTG1 cells were
treated with a CXCR2 antagonist (SB225002) or when
CXCR2 and IL-8 were neutralized by specific antibodies,
the inhibition of IL-8/CXCR2 signaling did not significantly
affect p53 expression or the phosphorylation of ERK1/2
and p53ser15 (Figure 4K). This result may indicate that the
CXCR2 antagonist and IL-8/CXCR2 antibodies have a
lower inhibitory effect on p21 expression (Figure 3F) as
compared with CXCR2 depletion (Figure 3C) and only
temporarily inhibit signalling. In this situation, the uninhib-
ited IL-8/CXCR2 signal can still induce a minor senescence
response to restrain a portion of the hPTTG1-induced
replication stress that provoked DDR. Hence, unlike
CXCR2 depletion, the CXCR2 antagonist and IL-8/CXCR2
antibodies did not induce severe DDR in MCF-7hPTTG1
cells.
CXCR2 modulates the role of hPTTG1 overexpression in
tumor growth and metastasis
To confirm whether hPTTG1-induced senescence affects
cell proliferation and DNA replication through a
CXCR2/p21-dependent mechanism, we carried out cell
proliferation and bromodeoxyuridine (BrdU) incorpora-
tion assays. In MCF-7 cells, hPTTG1 overexpression sig-
nificantly inhibited cell proliferation (Figure 5A) and
DNA replication (Figure 5B). Conversely, when CXCR2
or p21 was depleted, hPTTG1 overexpression accelerated
the proliferation and DNA replication of MCF-7 cells
(Figure 5A, B). These results indicate that a CXCR2/p21-
dependent mechanism is critical for hPTTG1-induced
senescence to inhibit cell proliferation and DNA
replication.
To understand the role of the hPTTG1/CXCR2 axis in
breast cancer development, we orthotopically trans-
planted control MCF-7Mock cells, MCF-7hPTTG1 cells,
and CXCR2-depleted MCF-7hPTTG1 cells into the fourth
mammary fat pad of severe combined immunodeficiency
(SCID) mice and monitored tumor growth weekly
(Figure 5C). Twelve weeks after transplantation, tumors
and lungs were harvested for further investigation. In
these mice, hPTTG1 overexpression dramatically inhib-
ited the tumor growth of MCF-7hPTTG1 cells (Figure 5C,
Dc). Conversely, when CXCR2 was depleted in MCF-
7hPTTG1 cells, hPTTG1 overexpression strongly acceler-
ated the growth of these tumors (Figure 5C, De, f) when
compared with CXCR2-knockdown MCF-7Mock cells
(Figure 5Db). To confirm the molecular link between
hPTTG1 and CXCR2/p21 signaling, we performed an
immunohistochemical (IHC) analysis in mouse tumor
samples. Compared with control MCF-7Mock tumors
(Figure 5Ea, b, c), hPTTG1 overexpression strongly
increased the expression of CXCR2 and p21 in MCF-
7hPTTG1 tumors (Figure 5Ef, g, h). In these tumors,
hPTTG1 overexpression induced strong nuclear locali-
zation of p21 (Figure 5Eh), which is a molecular marker
of cell-cycle arrest [40]. In addition, knockdown of
CXCR2 dramatically limited the expression of p21 in
CXCR2-depleted MCF-7hPTTG1 tumors (Figure 5Ek,
l, m). Supporting our in vitro data, CXCR2 depletion
strongly accelerated the proliferation of CXCR2-depleted
MCF-7hPTTG1 tumors, which displayed strong ki67 stain-
ing, even when p53 was highly induced (Figure 5En, o).
Taken together, our findings indicate that CXCR2 plays
an important role in inhibiting hPTTG1-induced tumor
growth and that it is critical for p21 induction.
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Figure 5 CXCR2/p21-dependent senescence inhibits hPTTG1-induced tumor growth. (A) In vitro growth curves were determined in MCF-
7Mockcells, MCF-7hPTTG1 cells, MCF-7CXCR2 cells, MCF-7Mock cells infected with shCXCR2-1, and MCF-7hPTTG1 cells infected with shGFP, shCXCR2-1,
shCXCR2-2, shp21-1, or shp21-2. (B) The colorimetric ELISA assay for BrdU incorporation was performed in representative cells. The results are
presented as the mean ± SEM (n = 3). **P < 0.01. (C) MCF-7Mock cells, MCF-7Mock cells infected with shCXCR2-1, MCF-7hPTTG1 cells, and MCF-
7hPTTG1 cells infected with shGFP, shCXCR2-1, or shCXCR2-2 were orthotopically injected into the fourth mammary fat pads of SCID mice. Tumor
growth was measured weekly. The experiments were terminated after 12 weeks because of the tumor burden. Representative tumors are shown
in (D); n = 6 per group per time point. Each time point is presented as the mean ± SEM. **P < 0.01. (D) Tumor weights were measured
12 weeks after orthotopic implantation of representative cells. The representative tumors are shown in the upper panel; n = 6 per group. The
results are presented as the mean ± SEM. *P < 0.05. (E) Representative tumors were embedded in paraffin and sectioned for immunohistologic
analysis of representative proteins. Original magnification, ×400. Scale bars, 25 μm.
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To determine the impact of the hPTTG1/CXCR2 axis
on metastasis, we examined lung metastases by perform-
ing H&E (hematoxylin and eosin) analysis of lung sec-
tions. In these mice, CXCR2-depleted MCF-7hPTTG1
cells metastasized to the lungs in significant numbers
12 weeks after implantation, whereas control MCF-7
cells and MCF-7hPTTG1 cells did not form lung meta-
static nodules (Figure 6A, B). Altogether, these results
reveal that CXCR2-dependent senescence modulates the
role of hPTTG1 overexpression in tumor growth and
metastasis. The evasion of CXCR2-dependent senes-
cence (loss of expression of CXCR2 or p21) is important
in restoring the oncogenic properties of hPTTG1 over-
expression to promote tumor growth and metastasis.
hPTTG1 affects CXCR2 expression in human invasive
ductal carcinomas
Invasive ductal carcinoma (IDC) is the most common
type of breast cancer [41] and potentially metastasizes to
bone, liver, or lung. Therefore, we investigated the clini-
cal relevance of hPTTG1 and CXCR2 expression in
human breast IDC specimens. Immunohistochemically
stained IDC specimens were scored on the basis of the
intensity of hPTTG1 nuclear staining and the percentage
of hPTTG1-positive tumor cells [13]. Moreover, the
intensity of CXCR2 membrane and cytoplasmic staining
in tumor cells was analyzed. In human IDCs (100 cases),
hPTTG1 was predominantly expressed in the nuclei (2+
and 3+, 86 of 100), whereas CXCR2 staining was present
in both the membrane and cytoplasm (2+ and 3+, 80 of
100) (Figure 7A, B). Of the 100 specimens evaluated, 75
demonstrated abundant expression of both hPTTG1 and
CXCR2, and their expression levels were significantly
associated with each other (Figure 7A, Patient A, Patient
B; and 7B, P < 0.001). Importantly, nine of 14 IDC speci-
mens that were scored as having weak hPTTG1 expres-
sion (1+ and 0+) also expressed CXCR2 at a very low
level (1+ and 0+) (Figure 7A, Patient C, and 7B). These
results indicate that the expression of hPTTG1 has an
important effect on CXCR2 induction in human IDCs.
To support further the molecular link of the hPTTG1/
CXCR2/p21 axis that we established in vitro and in vivo,
we analyzed the p21 expression status in these 100 IDC
specimens. The expression of p21 was positively correlated
with the expression of both CXCR2 (Figure 7C, P = 0.029)
and hPTTG1 (Figure 7D, P = 0.029), and these observa-
tions suggest that the hPTTG1/CXCR2 axis is important
for p21 induction in human IDCs.
In addition, we analyzed the expression status of p21 in
84 IDC specimens in which the hPTTG1 and CXCR2
expression was significantly correlated (Figure 7B, E). Of
the 75 specimens that expressed both hPTTG1 and
CXCR2 at high levels (hPTTG1: 2+/3+, CXCR2:2+/3+), 41
displayed strong (3+) or moderate (2+) p21 nuclear
staining (41 (54.67%) of 75), and 34 (45.33%) demon-
strated weak p21 expression (Figure 7E). Of the nine spe-
cimens that weakly expressed both hPTTG1 and CXCR2
(hPTTG1, 1+/0+; CXCR2, 1+/0+), seven also displayed
weak staining of p21 (Figure 7E). These results suggest
that p21 mediates hPTTG1/CXCR2-induced senescence.
The loss of p21 expression has been observed in several
types of cancer [40], and the loss of p21 expression in
hPTTG1/CXCR2 double-positive samples (34 (45.33%)
of 75) provides a reasonable explanation for how
hPTTG1-overexpressing cancer cells manage to escape
senescence. Moreover, the tumors that did not lose p21
expression (41 (54.67%) of 75) may carry a mutation in a
downstream mediator of hPTTG1/CXCR2/p21 signaling
to evade senescence, or the hPTTG1/CXCR2/p21-
expressing cells may represent only a portion of a tumor
composed of heterogeneous cell types.
The hPTTG1/CXCR2 axis plays an important role in
human breast cancer metastasis
To understand further the role of the hPTTG1/CXCR2
axis in breast cancer metastasis, we collected 50 human
primary IDCs and 50 matched lymph nodes with meta-
static carcinoma. According to an IHC analysis of
hPTTG1 and CXCR2 expression, we classified these pri-
mary IDCs and metastatic carcinomas into the following
four groups: hPTTG1 (2+,3+)/CXCR2 (2+,3+); hPTTG1
(2+,3+)/CXCR2 (1+,0+); hPTTG1 (1+,0+)/CXCR2(2+,3+);
and hPTTG1 (1+,0+)/CXCR2 (1+,0+).
Of the primary IDCs, 41 (82%) of 50 expressed both
hPTTG1 and CXCR2 at high levels, and only one speci-
men displayed weak staining of both hPTTG1 and CXCR2
(Figure 7F). This result implies that the hPTTG1/CXCR2
axis plays a metastasis-promoting role in primary tumors.
Interestingly, only 40% of the metastatic carcinomas
expressed both hPTTG1 and CXCR2 at high levels (2+
and 3+, 20 of 50 in metastatic LNs) (Figure 7F). The num-
ber of specimens weakly expressing both hPTTG1 and
CXCR2 increased from 2% (one of 50) in primary IDCs to
26% (13 of 50) in metastatic carcinomas (Figure 7F). Nota-
bly, eight patients demonstrated abundant expression of
both hPTTG1 and CXCR2 in primary IDCs but lost the
expression of both hPTTG1 and CXCR2 in metastatic car-
cinomas (Figure 7Ga, b, c, d). Nineteen patients displayed
abundant expression of both hPTTG1 and CXCR2 in both
primary and metastatic carcinomas (Figure 7Ge, f, g, h).
Clarifying the complexities of the combinations of
hPTTG1-induced senescence, hPTTG1-induced SASP
and hPTTG1-induced metastasis in human tumor speci-
mens is difficult. However, these findings have two possi-
ble implications. First, considering our findings in the in
vitro assays (Figure 3C) and human IDCs (Figure 7E), the
tumor cells that expressed hPTTG1 and CXCR2 at high
levels in both primary and metastatic tumors may escape
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Figure 6 CXCR2-dependent senescence restrains hPTTG1-induced metastasis. (A) Left column: Images of murine lungs 12 weeks after
orthotopic implantation of MCF-7Mock cells, MCF-7Mock cells stably infected with shCXCR2-1, and MCF-7hPTTG1 cells infected with shGFP or
shCXCR2-1. Right panel: H&E staining of lungs from mice bearing the indicated tumors; arrows indicate metastatic foci. Magnification, ×200. Scale
bars, 100 μm. (B) Lung metastases in mice bearing representative tumors were observed by performing H&E analysis of paraffin-embedded lung
sections. The numbers of metastatic nodules in the H&E stains were microscopically counted. Quantitative results of the lung metastasis of
representative cells (n = 6 per group) are presented as the mean ± SEM. **P < 0.01; ***P < 0.0001.
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Figure 7 Positive correlation between hPTTG1, CXCR2, and p21 expression in human breast invasive ductal carcinomas (IDCs). (A) The
expression pattern of hPTTG1, CXCR2, and p21 in representative tumor tissues of patients with breast IDC were immunohistochemically
analyzed. Tissues were scored as having strong (3+), moderate (2+) or weak expression (1+/0+). The criteria are described in the Materials and
methods. Original magnification, ×400. Scale bars, 25 μm. (B-D) The expression data for hPTTG1, CXCR2, and p21 in 100 IDC specimens. The
correlation between the indicated proteins was analyzed by using the Pearson c2 test. (E) The expression data for p21 in 84 IDC specimens in
which hPTTG1 expression was relevant to CXCR2 expression (the 84 specimens are marked with boxes in (B). (F) The expression data of hPTTG1
and CXCR2 in 50 primary IDC specimens and 50 matched metastatic carcinomas (upper panel). The specimens were classified into four groups:
hPTTG1(2+,3+)/CXCR2(2+,3+), hPTTG1(2+,3+)/CXCR2(1+,0+), hPTTG1(1+,0+)/CXCR2(2+,3+), and hPTTG1(1+,0+)/CXCR2(1+,0+). The percentage of
hPTTG1/CXCR2-stained specimens of each group is indicated in the lower panel. (G) The expression pattern of hPTTG1 and CXCR2 in
representative breast IDC and matched metastatic lymph nodes (LNs). Original magnification, ×400. Scale bars, 25 μm. (H) MDA-MB-231 cells
were stained with FITC-conjugated anti-CXCR2 or isotype control IgG for FACS analysis. (I) Cell lysates of MDA-MB-231, MCF-7, and MCF-10A cells
were collected for immunoblot analysis. (J) MDA-MB-231 cells were plated for senescence assays. The percentage of positively stained cells is
presented as the mean ± SEM (n = 3).
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senescence via the loss of p21 expression. In other words,
when the CXCR2/p21-dependent senescence pathway is
interrupted (that is, the loss of expression of p21), the
evasion of senescence may restore the metastatic poten-
tial of hPTTG1 overexpression, as strong staining of
hPTTG1 and CXCR2 in metastatic carcinomas was
observed (for example, Figure 7G, Patient 2). This con-
clusion is supported by our previous study [13] demon-
strating that hPTTG1 overexpression plays a critical role
in promoting the invasion and metastasis of MDA-MB-
231 cells that endogenously expressed hPTTG1 at a very
high level but expressed CXCR2 (Figure 7H) [42,43] and
p21 (Figure 7I) at a very low level and underwent weak
senescence (Figure 7J).
Second, when the CXCR2-dependent senescence path-
way is intact, it can restrict the growth and metastatic
potential of hPTTG1-overexpressing cancer cells. How-
ever, given the heterogeneity of breast cancer [41,44], dif-
ferent populations of cancer cells may cooperate to
achieve metastasis. Therefore, the hPTTG1-induced
SASP may benefit the metastasis of neighboring nonse-
nescent cancer cells, which would explain why the meta-
static nonsenescent cancer cells displayed low expression
levels of both hPTTG1 and CXCR2 in metastatic carci-
nomas (for example, Figure 7G, Patient 1).
hPTTG1-overexpressing senescent cells promote the
invasion and metastasis of neighboring non-senescent
cancer cells
To confirm the clinical implications described, we asked
whether hPTTG1-overexpressing senescent cells can pro-
mote the metastasis of neighboring nonsenescent cells.
Senescent cells have been shown to promote the tumor
growth and metastasis of neighboring cancer cells by
generating a tumor-promoting microenvironment
[45-47]. Therefore, we labeled MCF-7 cells with green
fluorescent protein (ZsGreen) and mixed these ZsGreen-
labeled cells (MCF-7ZsGreen, 0.5 × 105 cells) with MCF-
7Mock cells (0.5 × 105 cells) or MCF-7hPTTG1 cells (0.5 ×
105 cells). By performing cell migration and invasion
assays on these two cell mixtures, we found that MCF-
7hPTTG1 cells significantly promoted the migration and
invasion of MCF-7ZsGreen cells, whereas MCF-7Mock cells
did not (Figure 8A).
Furthermore, we orthotopically transplanted the cell
mixtures into SCID mice and examined lung metastasis 14
weeks after transplantation. When compared with mice
injected with the mixture of MCF-7ZsGreen (2 × 105 cells)
and MCF-7Mock cells (2 × 105 cells), mice injected with
the mixture of MCF-7ZsGreen (2 × 105 cells) and MCF-
7hPTTG1 cells (2 × 105 cells) displayed a significant reduc-
tion in tumor weight (Figure 8Ba, b). Both type of tumors
showed heterogeneous green fluorescence, which was
exhibited by the MCF-7ZsGreen cells (Figure 8Bc, d).
Interestingly, four of the six mice that received transplants
with the mixture of MCF-7ZsGreen and MCF-7hPTTG1 cells
displayed visible lung metastatic nodules (Figure 8Ca, b).
When we directly observed these metastatic nodules with
fluorescence microscopy, all visible nodules showed strong
green fluorescence (Figure 8Cd, e). Conversely, no obser-
vable metastatic nodules or fluorescent micrometastases
were found in the lungs of mice given transplants with the
mixture of MCF-7ZsGreen and MCF-7Mock cells (Figure
8Cc, f). With H&E analysis of lung sections, the mice
injected with the mixture of MCF-7ZsGreen and MCF-
7hPTTG1 cells exhibited a significant number of lung meta-
static nodules (Figure 8Cg, h), whereas mice injected with
MCF-7ZsGreen and MCF-7Mock cells did not exhibit meta-
static nodules (Figure 8Ci).
Tumor-associated macrophage infiltration has been
demonstrated to promote angiogenesis, invasion, metas-
tasis, and cancer chemoresistance [48,49]. To determine
whether hPTTG1-induced SASP provokes an inflamma-
tory response that would promote the metastasis of
MCF-7 cells in a mouse model, we examined mouse
macrophage infiltration by IHC staining of F4/80, a
mouse macrophage-specific marker. Tumors composed
of MCF-7ZsGreen and MCF-7Mock cells displayed weak
expression of both hPTTG1 and CXCR2 and were mildly
infiltrated by mouse macrophages (Figure 8D). Conver-
sely, tumors composed of MCF-7ZsGreen and MCF-
7hPTTG1 cells showed strong heterogeneous staining of
both hPTTG1 and CXCR2 and demonstrated severe
macrophage infiltration (Figure 8D). These results sug-
gest that hPTTG1-induced SASP instigates the inflam-
matory response and contributes to metastasis.
These data support the implications from the human
metastatic carcinomas (Figure 8E). When cells are cap-
able of inducing senescence, CXCR2-dependent senes-
cence can inhibit the proliferation and metastasis of
breast cancer cells. However, hPTTG1-induced SASP in
the tumor can provoke an inflammatory response and
promote the metastasis of nonsenescent neighboring
cells. In conclusion, our study elaborates on the role of
hPTTG1 in OIS regulation and provides novel evidence
by which hPTTG1-overexpressing cells remodel the
tumor microenvironment via hPTTG1-induced SASP
that promotes breast cancer metastasis.
Discussion
Our study identifies the role of hPTTG1 overexpression in
OIS regulation and breast cancer metastasis (Figure 8E).
First, we demonstrated that hPTTG1 overexpression rein-
forces senescence through a CXCR2/p21-dependent
mechanism. Second, CXCR2-dependent senescence is suf-
ficient to restrict the oncogenic potential of hPTTG1 over-
expression, and senescence evasion is important for
hPTTG1 to exert its oncogenic properties. Third, IHC
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analyses reveal a positive correlation between hPTTG1
and CXCR2 expression in human IDCs. Finally, we pro-
vide novel evidence that the hPTTG1-induced SASP plays
an important role in promoting breast cancer metastasis.
hPTTG1 is a strong oncogene that promotes the
malignant progression of cancers via a variety of
mechanisms [6,13,14], and the mechanisms of hPTTG1
accumulation have been investigated by many groups
[50-52]. These previous studies emphasized the impor-
tance of hPTTG1 overexpression in tumor development,
and in support of these studies, both our recent findings
[13] and the present study have elucidated the role of
hPTTG1 overexpression in breast cancer development
and metastasis.
Figure 8 hPTTG1-induced SASP promotes the metastasis of MCF-7 cells. (A) Migration and invasion assays in the representative cell
mixtures. Images show the migrating and invading fluorescent MCF-7 cells (MCF-7ZsGreen) in polycarbonate membrane filters (left panel). Original
magnification, ×200. Scale bars, 100 μm. Right panels: Quantitative results of the migrating and invading cells. The results are presented as mean
± SEM (n = 3). **P < 0.01. (B) Tumor weights were measured 14 weeks after orthotopic implantation of representative cell mixtures. The
representative tumors are shown in the left upper panel (a, b). The tumor sections were observed with fluorescence microscopy (c, d). Original
magnification, ×200. Scale bars, 100 μm. Right panel: Quantitative results of the tumor weight (n = 6). The results are presented as the mean ±
SEM. **P < 0.001. (C) Left upper panel: Images of murine lungs 14 weeks after orthotopic implantation of representative cell mixtures (a-c). Left
middle panel: Lung nodules observed with fluorescence microscopy (d-f). Original magnification, ×200. Scale bars, 100 μm. Left lower panel: H&E
stain of lungs from mice bearing the indicated tumors; arrows indicate metastatic foci. Original magnification, ×400. Scale bars, 25 μm. Right
panel: Quantitative results of the lung metastasis of representative cells (n = 6 per group). Data are presented as the mean ± SEM. (D)
Representative tumors were embedded in paraffin and sectioned for IHC analysis of representative proteins. (E) Schematic representation of the
role of the hPTTG1/CXCR2 axis in breast cancer development.
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In our previous study, we demonstrated that hPTTG1
overexpression can promote the migration and invasion
of MCF-7 cells [13]. However, in the present study, we
also demonstrated that hPTTG1 overexpression can rein-
force OIS in MCF-7 cells. OIS is a type of premature
senescence that does not occur in all cells [20,53,54]. The
hPTTG1-overexpressing cells that do not senesce may
still retain their capacity for migration and invasion.
Moreover, it is possible that hPTTG1/GEF-H1 signaling
and hPTTG1/CXCR2 signaling were coactivated in the
same cells and that even senescence can limit the prolif-
eration of these cells with higher hPTTG1-induced moti-
lities. Similar contradictory observations were also shown
in the first PTTG1 study: PTTG1 overexpression inhibits
cell proliferation but promotes cell transformation [1].
Although hPTTG1 overexpression can dramatically limit
MCF-7 cell growth, the growth rate of MCF-7hPTTG1
tumors was accelerated for 12 weeks after implantation
(Figure 1C). In these mice, lung metastases were
observed at approximately 16 to 18 weeks after trans-
plantation, whereas mice with transplanted control MCF-
7 cells did not form metastatic nodules in their lungs
[13]. Accumulating genetic mutations increase cancer
malignancies [55]. We speculate that the accumulating
hPTTG1-induced DNA damage provides opportunities
for cancer cells to evade senescence. In this situation,
senescence would be a selective pressure for senescence-
evading cells, and these senescence-evading cells may
need more time to grow and metastasize. However,
further studies should be conducted to address this issue.
Although several studies have provided convincing evi-
dences that hPTTG1 overexpression plays a tumor-pro-
moting role in various types of cancers [3,12-14,56], the
involvement of hPTTG1-induced senescence in cancer
development should be carefully considered. For exam-
ple, the microenvironment constructed by hPTTG1-
induced SASP increases the complexity of the role of
hPTTG1 in breast cancer tumorigenesis and metastasis.
To understand the specific role of hPTTG1-induced
senescence in tumorigenesis, we incorporated the con-
cept of intratumoral heterogeneity, which has long been
observed in breast cancer [44].
In a tumor composed of heterogeneous populations of
cancer cells, hPTTG1-overexpressed senescent cells may
benefit the growth and metastasis of neighboring senes-
cence-evading cells. We confirmed this hypothesis by
using MCF-7 cells in a coinjection assay in mice. Addi-
tionally, MCF-7 cells were originally isolated from meta-
static pleural effusions [57], but MCF-7 cells metastasize
and invade poorly in mouse models. Given the heteroge-
neity of breast cancer [41,44], we hypothesised that
hPTTG1-overexpressing senescent MCF-7 cells may cre-
ate a metastasis-promoting microenvironment to restore
the metastatic potential of MCF-7 cells, and our results
confirmed this hypothesis.
hPTTG1 overexpression has been shown to inhibit
cancer cell growth by activating p21 independent of p53
[32]. In this study, we provide evidence that the
hPTTG1/CXCR2 axis can induce p21 expression
through a p53-independent mechanism. Our findings
emphasize the importance of p21 in CXCR2-mediated
senescence. CXCR2 has been shown to play critical
roles in both tumor promotion and suppression
[25,28,58]. Moreover, depletion of CXCR2 has been
shown to alleviate the metastatic abilities of melanoma
[59,60] and metastatic breast cancer cells [61], but how
CXCR2 could play different roles in different cancer
cells remains unclear. To explain our finding that p21
knockdown inhibited hPTTG1/CXCR2-induced senes-
cence (Figure 3D, 5A, B), we speculate that p21 is a cri-
tical downstream mediator that determines the role of
CXCR2 in tumor development. In cells that were cap-
able of inducing p21 expression, CXCR2 induced a
senescence response via the activation of p21, whereas
in cells in which the p21-dependent mechanism was
interrupted, CXCR2 likely exerted its oncogenic proper-
ties when senescence was evaded. Senescence is an early
event in tumor development and can be induced only in
normal cells or low-malignant cancer cells with intact
senescence pathways [20]. Highly malignant cancer cells
isolated from late-stage tumors or metastatic nodules
typically have mutations in senescence pathways that
enable the escape from senescence [21,62]. Hence, the
loss of p21 or downstream mediators of CXCR2 signal-
ing may transform CXCR2 into a tumor-promoting fac-
tor, and this intriguing hypothesis will be further
addressed in future studies.
Conclusions
Overall, our findings provide novel molecular insights
into hPTTG1-induced senescence and an understanding
of the role of this process in breast cancer metastasis.
Thus, the expression status of hPTTG1 should be con-
sidered a risk factor for breast cancer metastasis as well
as a potential therapeutic target.
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